HU0002475A3 - Modified immunogenic pneumolysin compositions as vaccines - Google Patents

Modified immunogenic pneumolysin compositions as vaccines

Info

Publication number
HU0002475A3
HU0002475A3 HU0002475A HU0002475A HU0002475A3 HU 0002475 A3 HU0002475 A3 HU 0002475A3 HU 0002475 A HU0002475 A HU 0002475A HU 0002475 A HU0002475 A HU 0002475A HU 0002475 A3 HU0002475 A3 HU 0002475A3
Authority
HU
Hungary
Prior art keywords
vaccines
compositions
modified immunogenic
immunogenic pneumolysin
pneumolysin
Prior art date
Application number
HU0002475A
Other versions
HU0002475A2 (en
Original Assignee
Baxter Healthcare S A Wallisel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US5330697P priority Critical
Priority to US7345698P priority
Application filed by Baxter Healthcare S A Wallisel filed Critical Baxter Healthcare S A Wallisel
Priority to PCT/US1998/014716 priority patent/WO1999003884A2/en
Publication of HU0002475A2 publication Critical patent/HU0002475A2/en
Publication of HU0002475A3 publication Critical patent/HU0002475A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/831Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria
HU0002475A 1997-07-21 1998-07-21 Modified immunogenic pneumolysin compositions as vaccines HU0002475A3 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US5330697P true 1997-07-21 1997-07-21
US7345698P true 1998-02-02 1998-02-02
PCT/US1998/014716 WO1999003884A2 (en) 1997-07-21 1998-07-21 Modified immunogenic pneumolysin, compositions and their use as vaccines

Publications (2)

Publication Number Publication Date
HU0002475A2 HU0002475A2 (en) 2000-10-28
HU0002475A3 true HU0002475A3 (en) 2002-01-28

Family

ID=26731692

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002475A HU0002475A3 (en) 1997-07-21 1998-07-21 Modified immunogenic pneumolysin compositions as vaccines

Country Status (9)

Country Link
US (2) US6764686B2 (en)
EP (1) EP0998557A2 (en)
JP (1) JP2001510031A (en)
KR (1) KR100619350B1 (en)
AU (1) AU740956B2 (en)
CA (1) CA2297374A1 (en)
HU (1) HU0002475A3 (en)
NO (1) NO20000257L (en)
WO (1) WO1999003884A2 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
ES2300255T3 (en) 1999-03-19 2008-06-16 Glaxosmithkline Biologicals S.A. Vaccines against bacteria antigens.
GB9906437D0 (en) 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
ES2537737T3 (en) 2002-08-02 2015-06-11 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising lipooligosaccharides of immunotype L2 and / or L3 of Neisseria meningitidis of IgtB
AR041880A1 (en) 2002-11-01 2005-06-01 Glaxosmithkline Biolog Sa immunogenic composition
EP1558280B1 (en) 2002-11-07 2014-01-08 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
MXPA05009579A (en) * 2003-03-13 2005-11-17 Glaxosmithkline Biolog Sa Purification process for bacterial cytolysin.
CA2539715C (en) 2003-10-02 2015-02-24 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
US20060257421A1 (en) * 2004-02-13 2006-11-16 Martina Ochs Pneumolysin derivatives
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2005108419A1 (en) * 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
EP1791867A2 (en) * 2004-08-23 2007-06-06 Genesto A/S Binding member towards pneumolysin
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
PT1962899E (en) 2005-12-22 2011-10-19 Glaxosmithkline Biolog Sa Pneumococcal polysaccharide conjugate vaccine
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
SI2086582T1 (en) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
MX2009003325A (en) 2006-10-12 2009-04-09 Glaxosmithkline Biolog Sa Vaccine comprising an oil in water emulsion adjuvant.
KR101737464B1 (en) 2006-01-17 2017-05-18 아르네 포르스그렌 아베 A NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E - pE)
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP2032158A2 (en) * 2006-06-15 2009-03-11 Timothy John Mitchell Adjuvant compositions
PL2484375T3 (en) 2006-09-26 2018-09-28 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
JP5869206B2 (en) 2007-03-02 2016-02-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Novel methods and compositions
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
US8128939B2 (en) * 2007-04-13 2012-03-06 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
EA200901578A1 (en) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Vaccine containing conjugates of capsular polysaccharides streptococcus pneumoniae
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2612680B1 (en) 2008-04-16 2018-05-23 GlaxoSmithKline Biologicals SA Vaccine
EP2293815A4 (en) * 2008-05-22 2013-04-03 Childrens Medical Center Synergistic immunogenic fusion protein-polysaccharide conjugate
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
CN102712680B (en) * 2008-12-24 2016-06-22 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 Pneumolysin (PLY) polypeptide modified
JP5668049B2 (en) 2009-03-24 2015-02-12 ノバルティス アーゲー Combination of meningococcal factor H binding protein and pneumococcal saccharide conjugate
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
ES2651005T3 (en) 2010-03-09 2018-01-23 Biomedical Research Models, Inc. A new mucosal vaccination strategy for herpes simplex virus type-2
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CA2792689A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20130039947A1 (en) * 2010-03-12 2013-02-14 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012075428A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
AR086405A1 (en) * 2011-05-17 2013-12-11 Glaxosmithkline Biolog Sa Streptococcus pneumoniae vaccine
US20140294930A1 (en) * 2011-08-04 2014-10-02 The Regents Of The University Of California STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
US20150017191A1 (en) 2012-02-07 2015-01-15 Infectious Disease Research Institute Adjuvant formulations comprising tlr4 agonists and methods of using the same
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
HUE039215T2 (en) 2012-05-16 2018-12-28 Immune Design Corp Vaccines for hsv-2
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
CA2897398A1 (en) 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
JP6426706B2 (en) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3268037A2 (en) 2015-03-09 2018-01-17 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
BR112018071307A2 (en) 2016-04-18 2019-02-26 Celldex Therapeutics Inc agonistic antibodies that bind human CD40 and uses thereof
CN109562057A (en) 2016-05-16 2019-04-02 传染病研究所 Pegylated liposomal and application method
EP3458475A1 (en) 2016-05-16 2019-03-27 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use
WO2017210364A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
WO2018232257A1 (en) 2017-06-15 2018-12-20 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2121481C1 (en) 1988-12-16 1998-11-10 Де Стат Дер Недерланден Вертегенвордигд Дор де Министр Ван Велзейн, Волксгезондхейд эн Кюлтюр Modified pheumolysine recombinant plasmid, method of producing modified pheumolysine and vaccine
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
EP0687688A1 (en) 1993-12-17 1995-12-20 Universidad De Oviedo Antibodies against pneumolysine and their applications
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
CA2262748A1 (en) * 1996-08-12 1998-02-19 Board Of Regents, The University Of Texas System Defining epitopes of the outer membrane protein copb of moraxella catarrhalis

Also Published As

Publication number Publication date
US20010014332A1 (en) 2001-08-16
KR20010022271A (en) 2001-03-15
US20050070695A1 (en) 2005-03-31
WO1999003884A2 (en) 1999-01-28
AU8407898A (en) 1999-02-10
HU0002475A2 (en) 2000-10-28
US6764686B2 (en) 2004-07-20
AU740956B2 (en) 2001-11-15
JP2001510031A (en) 2001-07-31
WO1999003884A3 (en) 1999-04-08
EP0998557A2 (en) 2000-05-10
NO20000257D0 (en) 2000-01-19
CA2297374A1 (en) 1999-01-28
NO20000257L (en) 2000-03-21
KR100619350B1 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
EG24742A (en) Vaccine composition.
DE60016903D1 (en) Antiperspirant compositions
DE60027029D1 (en) Combined vaccine compositions
DE60045324D1 (en) vaccine composition
HK1129846A1 (en) Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient qs-21
GB9715751D0 (en) Formulations
IL129423D0 (en) Improved preparation for use as contrast agent
AU8395001A (en) Vaccines
GR990300017T1 (en) Influenza vaccine
ZA9802253B (en) Therapeutic compositions.
HK1043722A1 (en) Shapes for tooth whitening strips
PT1183217E (en) Improved cement-based compositions
HRP20010319A2 (en) Novel methods for therapeutic vaccination
AU2054802A (en) Vaccine
IL155072D0 (en) Vaccine
GB0020953D0 (en) Vaccine
ZA9811849B (en) Vaccine.
ZA9804969B (en) Vaccine.
ZA9807591B (en) Vaccine.
SG71879A1 (en) Controlled release compositions
AU7192801A (en) Cosmetic compositions
AU7328501A (en) Cosmetic compositions
ZA9107356B (en) Vaccine compositions
HU0400445A3 (en) Novel vaccine composition
IL193170A (en) Chimeric flavivirus vaccines

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees